PD-L1 Expression and Outcome in Patients with Metastatic Non-Small Cell Lung Cancer and EGFR Mutations Receiving EGFR-TKI as Frontline Treatment

BACKGROUND: Epidermal growth factor receptor (EGFR) mutations are most common in Eastern Asia, and frequencies of 30–50% have been reported. EGFR-tyrosine kinase inhibitors (TKIs) are recommended as first-line therapeutic options for non-small cell lung cancer (NSCLC) with sensitizing EGFR mutations...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Cheng-Yu, Lai, Yi-Chun, Wei, Yu-Feng, Chen, Chung-Yu, Chang, Shih-Chieh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8020052/
https://www.ncbi.nlm.nih.gov/pubmed/33833528
http://dx.doi.org/10.2147/OTT.S290445

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8020052/
https://www.ncbi.nlm.nih.gov/pubmed/33833528
http://dx.doi.org/10.2147/OTT.S290445

Ejemplares similares